Price
No data yet.
Social Signal Score
Analyst Ratings
30 analystsRevenue
$4.64MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Zachary Roberts
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 151
- Beta
- 0.48
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -2.91
Financials
Revenue
$4.64M-87.9%Net Income
$-42.68MEBITDA
$-39.69MFree Cash Flow
$-32.15M-643020.0%EPS (diluted)
$-0.13Shares Outstanding (diluted)
328.93M+647.4%Operating Expenses
$51.56MCash & Debt
$332.60MReturn of Capital
$0.00Revenue by Segment (annual)
$4.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-190.89M | $-0.87 |
| 2024 | $22.0K | $-257.59M | $-1.32 |
| 2023 | $95.0K | $-327.26M | $-2.09 |
| 2022 | $156.0K | $-340.41M | $-2.38 |
| 2021 | $114.09M | $-182.05M | $-1.34 |
| 2020 | $0.00 | $-250.22M | $-2.08 |
| 2019 | $0.00 | $-184.59M | $-1.83 |
| 2018 | $0.00 | $-211.50M | $-2.36 |
| 2017 | $0.00 | $-2.0K | $-0.00 |
Valuation
ALLOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.09%Social Signal Score
Mentions (9)
- Newszacks.com·24d ago·Neutral
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
Allogene Therapeutics Announces Participation in September Investor Conference SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
View source ↗ - Newszacks.com·49d ago·Negative
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
View source ↗ - Newszacks.com·53d ago·Neutral
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Allogene Therapeutics Q2 Earnings Call Highlights Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.15 per share
Typical surprise +17.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.13 vs $-0.17beat
- Wed, May 13$-0.18 vs $-0.19beat
- Thu, Mar 12$-0.17 vs $-0.25beat
- Thu, Nov 6$-0.19 vs $-0.23beat
- Wed, Aug 13$-0.23 vs $-0.28beat
- Tue, May 13$-0.28 vs $-0.28beat
Estimates and results for ALLO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALLO officers and directors.
- Bought
- $5.0m
- Sold
- $1.2m
1 trade
30 trades
- Douglas Earl Martinsold
- Yoshiyama Anniesold
- Beneski Benjamin Machinassold
- Beneski Benjamin Machinassold
- Chang David Dsold
- Beneski Benjamin Machinassold
- Beneski Benjamin Machinassold
- Chang David Dsold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALLO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.